ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

Robert J. Motzer, MD
Published: Tuesday, Sep 30, 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

In all, 168 patients who had progressed on anti-angiogenic drugs were randomized to receive 0.3, 2, or 10 mg/kg nivolumab every 3 weeks. Patients on the trial were heavily pretreated – receiving nivolumab as second-, third-, or fourth-line therapy.

The response rate seen in all three arms was approximately 20%, while median PFS ranged from 2.7 to 4.0 months. The most striking results from this trial, Motzer says, is that many responses were durable.

The median OS was longer than expected, Motzer says, as it ranged from 18.7 to 25.0 months. Nivolumab was well tolerated, too, as just 11% of patients experienced a grade 3/4 adverse event.

<<< View more from the 2014 ESMO Congress

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

In all, 168 patients who had progressed on anti-angiogenic drugs were randomized to receive 0.3, 2, or 10 mg/kg nivolumab every 3 weeks. Patients on the trial were heavily pretreated – receiving nivolumab as second-, third-, or fourth-line therapy.

The response rate seen in all three arms was approximately 20%, while median PFS ranged from 2.7 to 4.0 months. The most striking results from this trial, Motzer says, is that many responses were durable.

The median OS was longer than expected, Motzer says, as it ranged from 18.7 to 25.0 months. Nivolumab was well tolerated, too, as just 11% of patients experienced a grade 3/4 adverse event.

<<< View more from the 2014 ESMO Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x